• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

kempharm

KemPharm inks Apadaz licensing deal with KVK Tech

October 31, 2018 By Fink Densford

KemPharm, KVK Tech

KemPharm (NSDQ:KMPH) said yesterday it inked a collaborative licensing deal with KVK Tech to obtain U.S. commercial rights to the company’s FDA-approved Apadaz drug. Through the agreement, KemPharm is eligible to receive approximately $3.4 million in pre-launch payments and core cost reimbursement, including a $2 million milestone payment “related to the initial formulary adoption of Apadaz. […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals Tagged With: kempharm, kvktech

KemPharm inks drug discovery deal with AI-driven biopharma

October 23, 2018 By Sarah Faulkner

Kempharm logo updated

KemPharm (NSDQ:KMPH) said today that it inked a collaboration with twoXar to develop prodrug-based therapies for an array of therapeutic indications. According to the deal, twoXar’s artificial intelligence-based drug discovery technology will be used alongside KemPharm’s Ligand Activated Therapy platform to identify and develop new prodrug therapies. In conjunction with its deal with twoXar, KemPharm also inked a research and […]

Filed Under: Discovery, Featured, Pharmaceuticals, Wall Street Beat Tagged With: kempharm

KemPharm touts efficacy data for pediatric ADHD therapy

July 9, 2018 By Sarah Faulkner

kempharm

KemPharm (NSDQ:KMPH) touted top-line data from a pivotal efficacy and safety trial of its KP415 pediatric ADHD product. The company reported that KP415, which consists of serdexmethylphenidate and d-methylphenidate, met the primary efficacy endpoint in people with attention-deficit/hyperactivity disorder between the ages of 6 and 12 years. KemPharm’s KP415 capsule makes use of d-MPH hydrochloride as […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: kempharm

KemPharm wins FDA nod for short-term pain prodrug

February 23, 2018 By Sarah Faulkner

kempharm

Shares in KemPharm (NSDQ:KMPH) soared today after the company said that the FDA approved a re-submitted application for its pain-relief prodrug, Apadaz. The product, which combines benzhydrocodone and acetaminophen, is indicated for the short-term management of acute pain. The FDA rejected KemPharm’s first attempt at regulatory approval for Apadaz in 2016. Today’s win for KemPharm is […]

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: kempharm

KemPharm launches pivotal efficacy trial for extended-release ADHD prodrug

January 8, 2018 By Sarah Faulkner

kempharm

KemPharm (NSDQ:KMPH) has launched a pivotal efficacy trial of its extended-release prodrug product for the treatment of attention deficit hyperactivity disorder in children. The company’s classroom-style study is designed to support a potential label for KP415 that would include both early-onset and long duration treatment effect for ADHD. The 140-patient trial is slated to wrap up […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: kempharm

KemPharm partners to develop therapy for kids with Tourette’s syndrome and ADHD

October 5, 2017 By Sarah Faulkner

kempharm

KemPharm (NSDQ:KMPH) said yesterday that it inked a technology licensing and assignment deal with Genco Sciences to develop a treatment for kids with Tourette’s syndrome and ADHD. Genco has won orphan designation from the FDA for its pediatric Tourette’s syndrome product candidate. KemPharm said it plans to use Genco’s nanoparticulate amphetamine technology to develop a prodrug […]

Filed Under: Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: kempharm

KemPharm tackles pediatric ADHD using ligand-activated drug

September 14, 2017 By Sarah Faulkner

kempharm

Travis Mickle’s work developing better drugs for attention deficit hyperactivity disorder is deeply personal – he has ADHD and so do his children. After receiving his PhD in organic chemistry from the University of Iowa, Mickle went on to work at New River Pharmaceuticals, where he developed the leading treatment for ADHD, Vyvanse. Now he […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: kempharm

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS